STOCK TITAN

AVITA Medical Inc - RCEL STOCK NEWS

Welcome to our dedicated news page for AVITA Medical (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on AVITA Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AVITA Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AVITA Medical's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Summary
AVITA Medical reports Q2 2023 financial results: Commercial revenue of $11.7M, a 42% increase YoY. FDA approvals for full-thickness skin defects and repigmentation of vitiligo lesions. $68.8M in cash, no debt. Future milestones include FDA approval of RECELL GO by Dec 27, 2023. Financial guidance: Q3 2023 commercial revenue expected to be $13-14M, raising full year 2023 revenue to $51-53M. Gross margin for full year 2023 expected to be 83-85%. Q2 net loss of $10.4M. Conference call on Aug 10.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
Rhea-AI Summary
AVITA Medical has submitted a premarket approval supplement to the FDA for its RECELL GO device, which aims to streamline the production process of Spray-On Skin Cells. The automated workflow eliminates the need for manual management of skin samples and is expected to receive FDA approval in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
-
Rhea-AI Summary
AVITA Medical rejoins the Russell 3000 Index, expanding exposure to the investment community and broadening investor base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
Rhea-AI Summary
AVITA Medical, a regenerative medicine company, has appointed David O'Toole as its new Chief Financial Officer. O'Toole brings over 30 years of experience in global corporate finance and capital markets. He will play a critical role in executing the company's growth initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
management
-
Rhea-AI Summary
AVITA Medical receives FDA approval for expanded use of its RECELL System to treat full-thickness skin defects, significantly expanding market opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.96%
Tags
AVITA Medical Inc

Nasdaq:RCEL

RCEL Rankings

RCEL Stock Data

253.98M
24.81M
0.66%
28.08%
2.83%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Valencia

About RCEL

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.